Evidence map›Paper›PMID 36910122›Full record

ArticleJournal of thoracic disease2023

Anatomic lung resection after immune checkpoint inhibitors for initially unresectable advanced-staged non-small cell lung cancer: a retrospective cohort analysis.

Harry Etienne, Ludovic Fournel, Pierre Mordant, Bertrand Richard Delatour, Karel Pfeuty, Gil Frey, Agathe Seguin-Givelet, Alex Fourdrain, Christophe Lancelin, Pascal Berna and 4 more

Abstract read
In one paragraph

Article in Journal of thoracic disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Harry EtienneAP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Université, site Tenon, Service de Chirurgie Thoracique et Vasculaire, Paris, France.
Ludovic FournelAP-HP, Groupe Hospitalier Universitaire APHP-Université Descartes, site Cochin, Service de Chirurgie Thoracique, Paris, France.
Pierre MordantAP-HP, Groupe Hospitalier Universitaire APHP-Nord-Université de Paris, site Bichat-Claude Bernard, Service de Chirurgie Thoracique et Vasculaire, Paris, France.
Bertrand Richard DelatourCentre Hospitalier Universitaire de Rennes, Service de Chirurgie Cardiaque et Thoracique, Rennes, France.
Karel PfeutyCentre Hospitalier Général de Saint-Brieuc, Service de Chirurgie Thoracique, Saint-Brieuc, France.
Gil FreyCentre Hospitalier Universitaire de Grenoble, Service de Chirurgie Thoracique, Grenoble, France.
Agathe Seguin-GiveletInstitut Mutualiste Montsouris, Service de Chirurgie Thoracique, Paris, France.
Alex FourdrainCentre Hospitalier Universitaire de Amiens, Service de Chirurgie Thoracique, Amiens, France.
Christophe LancelinClinique du Grand Large, Service de Chirurgie Thoracique, Brest, France.
Pascal BernaCentre Hospitalier Universitaire de Amiens, Service de Chirurgie Thoracique, Amiens, France.
Antoine LegrasCentre Hospitalier Universitaire de Tours, Service de Chirurgie Thoracique et Vasculaire, Tours, France.
Marco AlifanoAP-HP, Groupe Hospitalier Universitaire APHP-Université Descartes, site Cochin, Service de Chirurgie Thoracique, Paris, France.
Patrick BaganCentre Hospitalier Général d'Argenteuil, Service de Chirurgie Thoracique et Vasculaire, Argenteuil, France.
Jalal AssouadAP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Université, site Tenon, Service de Chirurgie Thoracique et Vasculaire, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Patients with initially unresectable advanced non-small cell lung cancer (NSCLC) might experience prolonged responses under immune checkpoint inhibitors (ICIs). In this setting, Multidisciplinary Tumor Board (MTB) seldomly suggest surgical resection of the primary tumor with the ultimate goal to eradicate macroscopic residual disease. Our objective was to report the perioperative outcomes of patients who underwent anatomic lung resection in these infrequent circumstances. Methods: We set a retrospective multicentric single arm study, including all patients with advanced-staged initially unresectable NSCLC (stage IIIB to IVB) who received systemic therapy including ICIs and eventually anatomical resection of the primary tumor in 10 French thoracic surgery units from January 2016 to December 2020. Coprimary endpoints were in-hospital mortality and morbidity. Secondary endpoints were the rate of complete resection of the pulmonary disease, major pathologic response, risk factors associated with post-operative complications, and overall survival. Results: Twenty-one patients (median age 64, female 62%) were included. Eighteen patients (86%) progressed after first line chemotherapy and received second line ICI. The median time between diagnosis and surgery was 22 months [interquartile range (IQR) 18-35 months]. Minimally-invasive approach was used in 10 cases (48%), with half of these requiring conversion to open thoracotomy. Nine patients (43%) presented early post-operative complications, and one patient died from broncho-pleural fistula one month after surgery. Rates of complete resection of the pulmonary disease and major pathologic response were 100% and 43%, respectively. In univariable analysis, diffusing capacity for carbon monoxide (DLCO) was the only factor associated with the occurrence of postoperative complications (P=0.027). After a median follow-up of 16.0 months after surgery (IQR, 12.0-30.0 months), 19 patients (90%) were still alive. Conclusions: Anatomic lung resections appear to be a reasonable option for initially unresectable advanced NSCLC experiencing prolonged response under ICIs. Nonetheless, minimally invasive techniques have a low applicability and post-operative complications remains higher in patients who had lower DLCO values. The late timing of surgery may also contribute to complications.

Indexed as

anatomic lung resectionimmune checkpoint inhibitors (ICIs)Non-small cell lung cancers (NSCLCs)

Identifiers

PMID36910122
PMCPMC9992580

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.